Also trades as: 005257.KS (KSC) · $vol 0M

₩9,680.00 ($7.20)

-60.00 (-0.62%)

Weekly Expected Move ±2.6%

₩9180 ₩9430 ₩9680 ₩9930 ₩10180

KSC · Healthcare · Biotechnology · Tech Score Sell · Power 37 · ₩435.3B mcap · 24M float · 1.21% daily turnover

Revenue

$2.45T +11.2% ▲

5Y CAGR: +7.4%

Gross Profit

$659.6B +6.3% ▲

5Y CAGR: +4.5%

Operating Income

$35.0B +426.5% ▲

5Y CAGR: -13.1%

Net Income

-$69.5B -389.3% ▼

EPS (Diluted)

$-1531.06 -389.3% ▼

EBITDA

$142.2B -33.2% ▼

5Y CAGR: -4.9%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.84T	$2.08T	$2.06T	$2.20T	$2.45T
YoY Growth	+7.1%	+13.0%	-1.0%	+7.1%	+11.2%
Cost of Revenue	$1.21T	$1.38T	$1.45T	$1.58T	$1.79T
Gross Profit	$628.5B	$698.3B	$603.6B	$620.4B	$659.6B
Gross Margin	34.1%	33.6%	29.3%	28.1%	26.9%
R&D Expenses	$147.3B	$193.9B	$179.5B	$174.6B	$0
SG&A Expenses	$205.6B	$217.7B	$419.6B	$199.6B	$0
Operating Expenses	$542.2B	$627.2B	$620.0B	$631.1B	$624.6B
Operating Income	$86.2B	$72.0B	$2.6B	-$10.7B	$35.0B
Operating Margin	4.7%	3.5%	0.1%	-0.5%	1.4%
Interest Expense	$27.5B	$36.5B	$53.1B	$66.6B	$72.0B
Income Before Tax	$180.0B	$30.4B	-$81.1B	$42.5B	-$53.4B
Tax Expense	$52.4B	-$29.3B	-$9.5B	$53.6B	-$11.6B
Net Income	$55.3B	$32.8B	-$54.1B	$24.0B	-$69.5B
Net Margin	3.0%	1.6%	-2.6%	1.1%	-2.8%
EPS (Diluted)	$1222.00	$722.95	$-1192.38	$529.17	$-1531.06
EBITDA	$196.1B	$180.2B	$66.8B	$212.8B	$142.2B
Shares Outstanding	45M	45M	45M	45M	45M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$610.0B	$565.1B	$494.6B	$600.6B	$736.9B	$619.5B	$534.8B	$596.3B
Cost of Revenue	$427.2B	$413.0B	$355.8B	$411.3B	$557.0B	$467.8B	$386.4B	$431.4B
Gross Profit	$182.8B	$152.1B	$138.8B	$189.2B	$179.9B	$151.7B	$148.3B	$164.9B
Gross Margin	30.0%	26.9%	28.1%	31.5%	24.4%	24.5%	27.7%	27.7%
R&D Expenses	$40.0B	$54.9B	$37.6B	$38.8B	$34.8B	$46.1B	$35.9B	$40.1B
SG&A Expenses	$47.7B	$47.4B	$46.6B	$167.5B	$55.8B	$63.1B	$52.9B	$116.0B
Operating Expenses	$148.3B	$176.8B	$143.5B	$167.5B	$153.9B	$159.7B	$145.3B	$158.3B
Operating Income	$34.5B	-$24.7B	-$4.8B	$21.7B	$26.0B	-$6.7B	$3.1B	$6.6B
Operating Margin	5.7%	-4.4%	-1.0%	3.6%	3.5%	-1.1%	0.6%	1.1%
Interest Expense	$18.3B	$16.4B	$16.3B	$18.1B	$18.2B	$19.4B	$19.1B	$19.8B
Income Before Tax	$12.5B	$116.2B	$14.0B	$55.8B	$29.0B	-$152.2B	-$17.3B	$4.8B
Tax Expense	$6.0B	$46.1B	-$4.1B	-$7.1B	$10.0B	-$10.4B	$12.3B	$3.5B
Net Income	-$1.1B	$82.5B	$2.9B	$33.9B	$9.2B	-$115.5B	-$17.3B	$1.5B
Net Margin	-0.2%	14.6%	0.6%	5.7%	1.2%	-18.7%	-3.2%	0.3%
EPS (Diluted)	$-24.00	$1817.52	$64.60	$747.36	$202.00	$-2545.02	$-381.23	$34.04
EBITDA	$61.6B	$158.2B	$22.1B	$217.9B	$72.6B	$19.6B	$31.1B	$34.5B
Shares Outstanding	45M	45M	45M	45M	45M	45M	45M	45M

005250.KS KSC